Compounds > debrisoquin

debrisoquin and flecainide

debrisoquin has been researched along with flecainide in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19902 (25.00)18.7374
1990's2 (25.00)18.2507
2000's2 (25.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Bargetzi, MJ; Follath, F; Haefeli, WE; Meyer, UA1
Eichelbaum, M; Fischer, C; Gross, AS; Mikus, G1
Beckmann, J; Eichelbaum, M; Gross, AS; Gundert-Remy, U; Hertrampf, R; Mikus, G1
Eichelbaum, M; Fischer, C; Gross, AS; Gundert-Remy, U; Hertrampf, R; Mikus, G1

Other Studies

8 other study(ies) available for debrisoquin and flecainide

ArticleYear
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
    Journal of cardiovascular pharmacology, 1990, Volume: 15, Issue:5

    Topics: Adult; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Debrisoquin; Dextromethorphan; Ethanolamines; Flecainide; Humans; In Vitro Techniques; Kinetics; Male; Microsomes, Liver; Mixed Function Oxygenases; Phenotype; Sparteine

1990
Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.
    European journal of clinical pharmacology, 1991, Volume: 40, Issue:2

    Topics: Adult; Analysis of Variance; Dealkylation; Debrisoquin; Female; Flecainide; Half-Life; Humans; Hydrogen-Ion Concentration; Male; Polymorphism, Genetic; Protein Binding; Sparteine; Stereoisomerism; Urination

1991
The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.
    Clinical pharmacology and therapeutics, 1989, Volume: 45, Issue:5

    Topics: Adult; Analysis of Variance; Chromatography, High Pressure Liquid; Debrisoquin; Female; Flecainide; Humans; Isoquinolines; Kidney Diseases; Male; Metabolic Clearance Rate; Oxidation-Reduction; Phenotype; Sparteine

1989
Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.
    British journal of clinical pharmacology, 1989, Volume: 28, Issue:5

    Topics: Debrisoquin; Female; Flecainide; Genotype; Humans; Isoquinolines; Male; Phenotype; Sparteine; Stereoisomerism

1989